IL-12/IL-23 Neutralization Is Ineffective for Alopecia Areata in Mice and Humans

    December 2019 in “ ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology ”
    Luana dos Santos Ortolan, Sa Rang Kim, Sydney B. Crotts, Lucy Liu, Brittany G. Craiglow, Carlos Gustavo Wambier, Renato Soriani Paschoal, Brett King, Ali Jabbari
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary In this study, ustekinumab did not promote hair regrowth in human patients with alopecia areata or prevent disease development in an AA mouse model, suggesting limited efficacy for this treatment.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The document summarizes a study that found IL-12/IL-23 neutralization to be ineffective in treating alopecia areata (AA) in both a C3H/HeJ mouse model and in humans. In the mouse model, treatment with antibodies specific for IL-12/23 p40 or IL-23 p19 did not prevent hair loss. Similarly, a retrospective chart review of four patients with AA treated with ustekinumab, a drug that targets the p40 subunit, showed no hair regrowth. These results challenge the role of IL-12 and IL-23 in AA pathogenesis and their viability as treatment targets. The study suggests that randomized controlled trials are necessary to confirm these findings, acknowledging the small sample size of human patients as a limitation.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results